Hypothesis

Mechanistic basis

Aging thymus shows NLRP3 inflammasome activation driven by lipid overload, leading to caspase‑1 cleavage, IL‑1β/IL‑18 release, and suppression of IL‑7 in thymic epithelial cells (TECs)1. Concurrently, elevated IL‑6 promotes trans‑signaling via soluble IL‑6R (sIL‑6R), activating STAT3 in stromal and hematopoietic cells, which induces SOCS3 that blunts IL‑7‑mediated Bcl‑2 expression in naïve T cells2. We propose that IL‑1β released from NLRP3‑active macrophages and dendritic cells upregulates sIL‑6R production, amplifying IL‑6 trans‑signaling and creating a feedforward loop that sustains inflammasome activation and STAT3 signaling in the thymic niche.

Prediction

Combined pharmacological inhibition of NLRP3 (using MCC950) and selective blockade of IL‑6 trans‑signaling (using sgp130Fc, an inhibitor of the IL‑6/sIL‑6R complex) will produce synergistic restoration of thymic architecture, increased output of naïve T cells, and improved peripheral immune competence beyond that achieved by either monotherapy.

Experimental design

• Animals: 20‑month‑old C57BL/6 mice (n=10 per group).
• Groups: (1) Vehicle control; (2) MCC950 alone (50 mg/kg i.p. thrice weekly); (3) sgp130Fc alone (10 mg/kg i.p. twice weekly); (4) Combination MCC950 + sgp130Fc at same doses.
• Duration: 8 weeks.
• Readouts:
  • Thymic histology (H&E, FOXN1 immunostaining) to assess cortical‑medullary organization.
  • Flow cytometry of thymic subsets (DN, DP, SP CD4/CD8) and peripheral naïve (CD62L^hi CD44^lo) T cells.
  • TCRβ repertoire sequencing for diversity indices.
  • Cytokine profiling (IL‑1β, IL‑6, sIL‑6R, IL‑7) in thymic lysates and serum.
  • Phospho‑STAT3 and cleaved caspase‑1 levels by Western blot in sorted TECs and macrophages.
  • Functional assays: ex vivo IL‑2 production after anti‑CD3/CD28 stimulation; survival after sub‑lethal LPS challenge.

Expected outcomes

• Monotherapy groups will show moderate improvements: MCC950 reduces caspase‑1 cleavage and IL‑1β, modestly increasing TEC IL‑7; sgp130Fc lowers p‑STAT3 and SOCS3, enhancing Bcl‑2 in naïve T cells.
• The combination group is predicted to:
  1. Exhibit the greatest reduction in thymic NLRP3 activity (↓ cleaved caspase‑1) and IL‑6 trans‑signaling (↓ sIL‑6R, ↓ p‑STAT3).
  2. Restore IL‑7 expression in TECs to youthful levels.
  3. Yield a 2‑3‑fold increase in total thymic cellularity and naïve T cell output versus control, exceeding the sum of individual effects (synergy).
  4. Produce a broader TCR repertoire (higher Shannon entropy) and heightened IL‑2 response.
  5. Confer improved survival post‑LPS, indicating enhanced peripheral innate immunity.

Falsifiability

If the combination fails to surpass the additive effect of the monotherapies on any primary readout (thymic cellularity, naïve T cell frequency, TCR diversity), the hypothesis is refuted. Likewise, absence of decreased sIL‑6R or p‑STAT3 in the combination group would invalidate the proposed feedforward loop.

Broader impact

Validating this synergy would provide a mechanistic rationale for combined inflammasome and IL‑6 trans‑signaling therapeutics to combat immunosenescence, with potential translational relevance for age‑related vaccine responsiveness and inflammasome‑linked neurodegeneration8.